{"id":1378,"date":"2026-06-18T19:03:17","date_gmt":"2026-06-18T19:03:17","guid":{"rendered":"https:\/\/www.lebihan.de\/industry-pharma\/"},"modified":"2026-10-20T10:23:53","modified_gmt":"2026-10-20T10:23:53","slug":"industry-pharma","status":"publish","type":"page","link":"https:\/\/www.lebihan.de\/en\/industry-pharma\/","title":{"rendered":"Industry – Pharma"},"content":{"rendered":"
\n
\"Pharma<\/div>
\n
\n
\n <\/svg>Pharma & Life Sciences<\/span>\n

Mastering Innovation, Market Access, and Resilience Simultaneously.<\/h1>\n

Development programs are becoming more scientifically demanding, regulatory requirements are changing, and global supply chains remain under pressure. At the same time, R&D portfolios must be focused, and investments concentrated where scientific prospects, patient needs, and economic potential converge. <\/p>\n

\n Schedule an initial consultation \u2192<\/a>\n How we support you \u2192<\/a> <\/div>\n <\/div>\n <\/div>\n <\/div>\n<\/section><\/div>\n
\n
The Starting Point<\/span>

When innovation pressure meets new regulatory and economic realities.<\/h2>

The pharmaceutical industry is under high innovation pressure and increasing international competition. New modalities expand therapeutic possibilities but also increase development risks and requirements for evidence, production, and market access. Simultaneously, regulatory frameworks and demands for resilient production and supply chains are changing. For companies, this increases the pressure to focus development programs early and concentrate capital, capacities, and management attention on the most promising assets. <\/p><\/div>\n